



Amvuttra in Qatar

The MOPH named-patient coordination pathway — indicative 2026

NEUROLOGY · HEREDITARY ATTR AMYLOIDOSIS

The clinical situation

Amvuttra (vutrisiran) is an FDA-approved GalNAc-conjugated siRNA that silences hepatic TTR production, indicated for hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN), dosed 25 mg SC every three months. Manufactured by Alnylam. Refrigerated shipment is required; vitamin A supplementation is recommended during treatment due to TTR-mediated retinol transport.

The pathway, 5 steps

- 1 Consultation & genetic confirmation.** Treating neurologist or cardiologist confirms TTR variant and hATTR-PN phenotype; baseline neurologic and cardiac assessment documented.
- 2 Treating centre & prescription confirmed.** A Qatari tertiary centre (Doha) issues the prescription and commits to quarterly SC administration.
- 3 MOPH named-patient application.** Clinical rationale, genetic report, prescription, and product details are filed with MOPH for import clearance.
- 4 US-side sourcing & cold-chain logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner; refrigerated shipment booked to administration date.
- 5 Administration & monitoring.** Quarterly SC injection in clinic; vitamin A supplementation, neurologic, and cardiac monitoring per label.

Indicative economics

Reference US cash-pay range: USD 130,000–160,000 per quarterly dose drug-only. Cold-chain logistics, MOPH documentation, clinic fees, and concierge coordination are incremental. Full transparent quote at intake.

Indicative first-dose timing

7–14 days from a complete MOPH application to first-dose delivery, once cohort intake opens. Indicative — not guaranteed.

Reserve Meds's role

Sourcing. US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** MOPH named-patient package with genetic confirmation. **Logistics.** Cold-chain, temperature-monitored shipment coordination to the administering clinic. **Concierge case lead.** Named point of contact for family and physician through the full process. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating specialist.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Amvuttra × Qatar first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemed.com/access-guides/amvuttra-qatar.html



SCAN TO JOIN

Reserve Meds · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.

reservemed.com · hello@reservemed.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team